Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Wall passivation for unstable angina

M Lettino1, F Dailey-Sterling, L Badimon

  • 1Cardiovascular Biology Research Laboratories, Mount Sinai School of Medicine, New York, NY 10029, USA.

Seminars in Interventional Cardiology : SIIC
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HDL therapy today: from atherosclerosis, to stent compatibility to heart failure.

Annals of medicine·2019
Same author

LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Drugs of today (Barcelona, Spain : 1998)·2019
Same author

Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis?

Drugs of today (Barcelona, Spain : 1998)·2019
Same author

Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: comment.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Niacin is still beneficial. Implications from an updated meta-regression analysis.

Acta cardiologica·2016
Same author

Muramidase: A useful monocyte/macrophage immunocytochemical marker in swine, of special interest in experimental cardiovascular disease.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015
Same journal

Atherectomy plus stenting: what do we gain?

Seminars in interventional cardiology : SIIC·2001
Same journal

The place of directional coronary atherectomy for the treatment of in-stent restenosis.

Seminars in interventional cardiology : SIIC·2001
Same journal

The place of rotablator for treatment of in-stent restenosis.

Seminars in interventional cardiology : SIIC·2001
Same journal

Directional coronary atherectomy: optimal atherectomy trials and new combined strategies with coronary stents.

Seminars in interventional cardiology : SIIC·2001
Same journal

Further insights into coronary debulking: the EUROCARE trial of directional atherectomy and the PACT trial of pullback atherectomy.

Seminars in interventional cardiology : SIIC·2001
Same journal

Morphological analysis of atherosclerotic plaque retrieved by coronary atherectomy.

Seminars in interventional cardiology : SIIC·2001
See all related articles

Platelet aggregation in coronary arteries drives arterial thrombosis and ischemia in unstable angina. Novel anti-platelet therapies, including direct thrombin inhibitors and glycoprotein IIb/IIIa antagonists, offer improved control of vascular occlusion.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Atherosclerotic plaque disruption is key to arterial thrombosis and ischemia.
  • Platelets are central to unstable angina pathogenesis, causing obstruction and thrombus extension.
  • Vascular occlusion is the primary target in unstable angina treatment.

Purpose of the Study:

  • To summarize the role of the vessel wall and platelets in arterial thrombosis.
  • To describe pharmacological approaches for platelet passivation in unstable angina.

Main Methods:

  • Review of current literature on arterial thrombosis and unstable angina.
  • Analysis of the interaction between the vessel wall and platelets.
  • Evaluation of existing and novel pharmacological agents for passivation.

Related Experiment Videos

Main Results:

  • Platelet aggregation can lead to mechanical obstruction and fibrin deposition.
  • Direct thrombin inhibitors and glycoprotein IIb/IIIa receptor antagonists show promise for passivation.
  • Understanding vessel wall-platelet interactions is crucial for therapeutic development.

Conclusions:

  • Effective control of unstable angina requires managing the acute disease process.
  • Novel anti-platelet agents may offer superior passivation compared to current therapies.
  • Targeting platelet activity is essential for preventing vascular occlusion in unstable angina.